Search Results - "Thomas, Melodie"

Cetuximab: adverse event profile and recommendations for toxicity management by Thomas, Melodie

“…Cetuximab (Erbitux, IMC-C225, ImClone Systems Incorporated, New York, NY) is a monoclonal antibody targeted to the epidermal growth factor receptor. Expression…”
Get full text

Cetuximab: Adverse Event Profi le and Recommendations for Toxicity Management by Thomas, Melodie

Get full text

Epidermal Growth Factor Receptor Tyrosine Kinase Inhibitors: Application in Non-Small Cell Lung Cancer by Thomas, Melodie

“…Despite treatment advances over the past decade, long-term survival for patients with non-small cell lung cancer (NSCLC) remains poor, and treatment options…”
Get full text

Overview of clinical trials with epidermal growth factor receptor inhibitors in advanced non-small cell lung cancer by Thomas, Melodie

“…To provide an overview of the clinical development of ZD1839 and other epidermal growth factor receptor (EGFR) inhibitors in the treatment of advanced…”
Get full text

Phase I trial of docetaxel administered by weekly infusion in patients with advanced refractory cancer by Hainsworth, J D, Burris, 3rd, H A, Erland, J B, Thomas, M, Greco, F A

“…Docetaxel is a highly active antineoplastic agent; however, grade IV leukopenia occurs in the large majority of patients treated with a dose of 100 mg/m2 every…”
Get more information

Preoperative therapy with concurrent paclitaxel/carboplatin/infusional 5-FU and radiation therapy in locoregional esophageal cancer: Final results of a Minnie Pearl Cancer Research Network phase II trial by MELUCH, Anthony A, GRECO, F. Anthony, HAINSWORTH, John D, GRAY, James R, THOMAS, Melodie, SUTTON, Valerie M, DAVIS, J. Lucian, KALMAN, Leonard A, SHAFFER, Don W, YOST, Kathleen, RINALDI, David A

“…This phase II study was designed to determine the feasibility, toxicity, and therapeutic efficacy of a novel outpatient combined-modality preoperative regimen…”
Get full text

Single-Agent Gefitinib in Patients with Untreated Advanced Non–Small-Cell Lung Cancer and Poor Performance Status: A Minnie Pearl Cancer Research Network Phase II Trial by Spigel, David R., Hainsworth, John D., Burkett, Emily R., Burris, Howard A., Yardley, Denise A., Thomas, Melodie, Jones, Suzanne F., Dickson, Natalie R., Scullin, Daniel C., Bradof, James E., Rubinsak, James R., Brierre, Joseph E., Greco, F. Anthony

“…BACKGROUND: Patients with advanced non–small-cell lung cancer (NSCLC) and poor performance status (PS) are often excluded from trials. Gefitinib is a safe oral…”
Get full text

Paclitaxel, carboplatin, and extended-schedule etoposide in the treatment of small-cell lung cancer: comparison of sequential phase II trials using different dose-intensities by Hainsworth, J D, Gray, J R, Stroup, S L, Kalman, L A, Patten, J E, Hopkins, L G, Thomas, M, Greco, F A

“…In two sequential phase II studies, we evaluate the feasibility and efficacy of adding paclitaxel to a standard platinum/etoposide regimen in the first-line…”
Get more information

One-hour paclitaxel infusions: review of safety and efficacy by Greco, F A, Thomas, M, Hainsworth, J D

“…Paclitaxel has emerged as one of the most active anticancer agents in clinical oncology. Hypersensitivity reactions encountered in the clinical development of…”
Get more information

Gefitinib in the treatment of advanced, refractory non-small-cell lung cancer: results in 124 patients by Hainsworth, John D, Mainwaring, Mark G, Thomas, Melodie, Porter, 3rd, Lester L, Gian, Victor G, Jones, Suzanne F, Greco, F Anthony

“…To evaluate the feasibility, toxicity, and efficacy of oral gefitinib (ZD1839, Iressa) in patients with refractory non-small-cell lung cancer (NSCLC) treated…”
Get full text

Prolonged administration of oral etoposide in non-small-cell lung cancer: a phase II trial by Waits, T M, Johnson, D H, Hainsworth, J D, Hande, K R, Thomas, M, Greco, F A

“…The trial was undertaken to investigate the activity and toxicity of a prolonged schedule of oral etoposide in the treatment of advanced non-small-cell lung…”
Get more information

Paclitaxel, carboplatin, and vinorelbine in the treatment of advanced non-small cell lung cancer: a phase II trial of the Minnie Pearl Cancer Research Network by Hainsworth, J D, Burris, 3rd, H A, Morrissey, L H, Thomas, M, Erland, J B, Butts, J A, Joseph, G, Kalman, L, Greco, F A

“…To evaluate the feasibility, toxicity, and efficacy of adding vinorelbine to the paclitaxel/carboplatin combination in the treatment of advanced non-small cell…”
Get more information

Paclitaxel, carboplatin, and extended-schedule oral etoposide for small-cell lung cancer by Hainsworth, J D, Hopkins, L G, Thomas, M, Greco, F A

“…We evaluated the feasibility and efficacy of combination paclitaxel (Taxol) (via 1-hour infusion), carboplatin (Paraplatin), and oral etoposide (VePesid) in…”
Get more information

Carboplatin plus oral etoposide in the management of advanced, non-small cell lung cancer: preliminary results of a Vanderbilt trial by Johnson, D H, DeVore, R, Greco, F A, Walls, J, Thomas, M, Hande, K R, Hainsworth, J D

“…Twenty-eight patients with unresectable, metastatic non-small cell lung cancer (NSCLC) were treated with carboplatin/oral etoposide. Carboplatin was…”
Get more information

Determinants of information technology strategic performance: An analysis of firm performance, IT performance, IT investment intensity and IT governance in the health care sector by Mayberry-Stewart, Melodie I. Thomas

“…The goal of this study in health care was to examine the relationships between IT Performance, Firm Performance, IT Investments, and IT Governance by examining…”
Get full text

Preoperative combined modality therapy with paclitaxel, carboplatin, prolonged infusion 5-fluorouracil, and radiation therapy in localized esophageal cancer: preliminary results of a Minnie Pearl Cancer Research Network phase II trial by Meluch, A A, Hainsworth, J D, Gray, J R, Thomas, M, Whitworth, P L, Davis, J L, Greco, F A

“…To evaluate the feasibility, toxicity, and therapeutic efficacy of 1-hour paclitaxel, carboplatin, continuous low-dose infusional 5-fluorouracil, and…”
Get more information

Determinants of information technology strategic performance: An analysis of firm performance, IT performance, IT investment intensity and IT governance in the health care sector by Mayberry-Stewart, Melodie I. Thomas

“…The goal of this study in health care was to examine the relationships between IT Performance, Firm Performance, IT Investments, and IT Governance by examining…”
Get full text